Iovance Biotherapeutics Stock Today
| IOVA Stock | USD 10.97 2.48 18.44% |
Performance4 of 100
| Odds Of DistressLess than 10
|
Iovance Biotherapeutics is trading at 10.97 as of the 12th of May 2024, a -18.44 percent decrease since the beginning of the trading day. The stock's open price was 13.45. Iovance Biotherapeutics has less than a 10 % chance of experiencing some financial distress in the next two years of operation, but did not have a good performance during the last 90 trading days. Equity ratings for Iovance Biotherapeutics are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 12th of February 2024 and ending today, the 12th of May 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 15th of October 2010 | Category Healthcare | Classification Health Care |
Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patients immune system to eradicate cancer cells. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California. The company has 279.83 M outstanding shares of which 50.06 M shares are currently shorted by private and institutional investors with about 8.74 trading days to cover. More on Iovance Biotherapeutics
Moving together with Iovance Stock
| 0.85 | VTYX | Ventyx Biosciences | PairCorr |
Follow Valuation Options Odds of Bankruptcy
Financial Report 14th of May 2024
Iovance Stock Highlights
Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. Iovance Biotherapeutics' investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Iovance Biotherapeutics or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
| Thematic Idea | Cancer Fighters (View all Themes) | ||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Biotechnology, NASDAQ Health Care, Cancer Fighters, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | ||||
| Average Analyst Recommendation Analysts covering Iovance Biotherapeutics report their recommendations after researching Iovance Biotherapeutics' financial statements, talking to executives and customers, or listening in on Iovance Biotherapeutics' conference calls. The current trade recommendation is based on an ongoing consensus estimate among financial analysts covering Iovance Biotherapeutics. The Iovance consensus assessment is calculated by taking the average forecast from all of the analysts covering Iovance Biotherapeutics. | |||||
Iovance Biotherapeutics' financial strength is of vital concern to both outside investors and internal stakeholders. Efficiency and cost control are keys to Iovance Biotherapeutics' success, along with its ability to generate sufficient cash flow to pay bills, repay debt, and make a consistent year-to-year profit. | |||||
Financial leverage usually refers to the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Iovance Biotherapeutics' financial leverage. It provides some insight into what part of Iovance Biotherapeutics' total assets is financed by creditors.
| |||||
Iovance Biotherapeutics (IOVA) is traded on NASDAQ Exchange in USA. It is located in 825 Industrial Road, San Carlos, CA, United States, 94070 and employs 557 people. Iovance Biotherapeutics is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Mid-Cap' category with a current market capitalization of 3.07 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Iovance Biotherapeutics's market, we take the total number of its shares issued and multiply it by Iovance Biotherapeutics's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Iovance Biotherapeutics conducts business under Biotechnology sector and is part of Health Care industry. The entity has 279.83 M outstanding shares of which 50.06 M shares are currently shorted by private and institutional investors with about 8.74 trading days to cover.
Iovance Biotherapeutics currently holds about 424.46 M in cash with (361.82 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.69.
Check Iovance Biotherapeutics Probability Of Bankruptcy
Ownership AllocationIovance Biotherapeutics has a total of 279.83 Million outstanding shares. The majority of Iovance Biotherapeutics outstanding shares are owned by outside corporations. These institutional investors are usually referred to as non-private investors looking to purchase positions in Iovance Biotherapeutics to benefit from reduced commissions. Consequently, third-party entities are subject to a different set of regulations than regular investors in Iovance Biotherapeutics. Please pay attention to any change in the institutional holdings of Iovance Biotherapeutics as this could imply that something significant has changed or is about to change at the company. Please note that no matter how many assets the company holds, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Iovance Ownership Details
Iovance Stock Price Odds Analysis
What are Iovance Biotherapeutics' target price odds to finish over the current price? Depending on a normal probability distribution, the odds of Iovance Biotherapeutics jumping above the current price in 90 days from now is about 85.16%. The Iovance Biotherapeutics probability density function shows the probability of Iovance Biotherapeutics stock to fall within a particular range of prices over 90 days. Given the investment horizon of 90 days the stock has a beta coefficient of 2.9234. This usually indicates as the benchmark fluctuates upward, the company is expected to outperform it on average. However, if the benchmark returns are projected to be negative, Iovance Biotherapeutics will likely underperform. Additionally, iovance Biotherapeutics has an alpha of 0.4694, implying that it can generate a 0.47 percent excess return over NYSE Composite after adjusting for the inherited market risk (beta).
Based on a normal probability distribution, the odds of Iovance Biotherapeutics to move above the current price in 90 days from now is about 85.16 (This Iovance Biotherapeutics probability density function shows the probability of Iovance Stock to fall within a particular range of prices over 90 days) .
Iovance Stock Institutional Holders
Institutional Holdings refers to the ownership stake in Iovance Biotherapeutics that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Iovance Biotherapeutics' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Iovance Biotherapeutics' value.| Instituion | Recorded On | Shares | |
| Balyasny Asset Management Llc | 2023-12-31 | 3.9 M | |
| Morgan Stanley - Brokerage Accounts | 2023-12-31 | 3.7 M | |
| Dimensional Fund Advisors, Inc. | 2023-12-31 | 3.5 M | |
| Mpm Oncology Impact Management Lp | 2023-12-31 | 3.3 M | |
| T. Rowe Price Associates, Inc. | 2023-12-31 | 3.3 M | |
| Jpmorgan Chase & Co | 2023-12-31 | 2.8 M | |
| Credit Suisse First Boston (csfb) | 2023-12-31 | 2.8 M | |
| Principal Financial Group Inc | 2023-12-31 | 2.6 M | |
| Northern Trust Corp | 2023-12-31 | 2.2 M | |
| Vanguard Group Inc | 2023-12-31 | 22.8 M | |
| Mhr Fund Management Llc | 2023-12-31 | 20 M |
Iovance Biotherapeutics Historical Income Statement
Iovance Biotherapeutics Income Statement is one of the three primary financial statements used for reporting Iovance's overall financial performance over a current year or for a given accounting period. An Income Statement sometimes referred to as the statement of Iovance Biotherapeutics revenue and expense. Iovance Biotherapeutics Income Statement primarily focuses on the company's revenues and expenses during a particular period.
At present, Iovance Biotherapeutics' Depreciation And Amortization is projected to increase significantly based on the last few years of reporting. The current year's Interest Expense is expected to grow to about 3.6 M, whereas Operating Income is projected to grow to (437.5 M). View More FundamentalsIovance Stock Against Markets
Picking the right benchmark for Iovance Biotherapeutics stock is fundamental to making educated investment choices. Many naive investors compare their positions with the S&P 500 or with the Nasdaq. But these benchmarks are not all-inclusive and generally should be used only for large-capitalization equities or stock offerings from large companies. When the price of a selected benchmark declines in a down market, there may be an uptick in Iovance Biotherapeutics stock price where buyers come in believing the asset is cheap. The opposite is true when the market is bullish; so, accurately picking the benchmark for Iovance Biotherapeutics is critical whether you are bullish or bearish towards Iovance Biotherapeutics at a given time. Please also check how Iovance Biotherapeutics' historical prices are related to one of the top price index indicators.
Be your own money manager
Our tools can tell you how much better you can do entering a position in Iovance Biotherapeutics without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Companies Directory Now
Companies DirectoryEvaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals |
| All Next | Launch Module |
Iovance Biotherapeutics Corporate Management
Elected by the shareholders, the Iovance Biotherapeutics' board of directors comprises two types of representatives: Iovance Biotherapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Iovance. The board's role is to monitor Iovance Biotherapeutics' management team and ensure that shareholders' interests are well served. Iovance Biotherapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Iovance Biotherapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Esq JD | President, CEO | Profile | |
| Igor Bilinsky | Chief Officer | Profile | |
| Friedrich MD | Chief Officer | Profile | |
| Howard MBA | Chief Officer | Profile | |
| JeanMarc MBA | Chief Officer | Profile | |
| Sara Pellegrino | Vice Relations | Profile | |
| Madan Jagasia | Ex Affairs | Profile |
How to buy Iovance Stock?
Before investing in Iovance Biotherapeutics, you must ensure you fully understand your financial goals and how diversified (or not) your overall investments are now. Then, after you clearly understand your investment objectives, consider investing in Iovance Biotherapeutics. To buy Iovance Biotherapeutics stock, you can follow these steps:- Choose a brokerage firm: You need to select a brokerage firm to buy shares of Iovance Biotherapeutics. Some popular options include Charles Schwab, Fidelity, TD Ameritrade, and Robinhood.
- Open an account: Once you have chosen a brokerage firm, you will need to open an account. You will be required to provide personal information, such as your name, address, and Social Security number.
- Fund your account: You will need to deposit funds into your brokerage account to purchase Iovance Biotherapeutics stock. You can do this by transferring funds from your bank account or other investment accounts.
- Place your order: Once you have located Iovance Biotherapeutics stock in your brokerage account, you can place your order to buy it. You will need to specify the number of shares you want to buy and the price you are willing to pay.
- Monitor your investment: After you have purchased Iovance Biotherapeutics stock, you should monitor your investment to track its performance and make informed decisions about buying, selling, or holding the stock
It's important to note that investing in stocks, such as Iovance Biotherapeutics, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember various factors, including economic indicators, change in net worth, political events, company-specific news, and investor sentiment, can influence the stock market. These factors can cause fluctuations in stock prices and lead to market volatility affecting your buy or sell decision. However, volatility can also present opportunities for investors to make gains by buying stocks when prices are low and selling when they are high. It's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. For more information on how to buy Iovance Stock please use our How to Invest in Iovance Biotherapeutics guide.
Already Invested in Iovance Biotherapeutics?
The danger of trading Iovance Biotherapeutics is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Iovance Biotherapeutics is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Iovance Biotherapeutics. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Iovance Biotherapeutics is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
When determining whether Iovance Biotherapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Iovance Biotherapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Iovance Biotherapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Iovance Biotherapeutics Stock: Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Iovance Biotherapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in real. For information on how to trade Iovance Stock refer to our How to Trade Iovance Stock guide.You can also try the Equity Valuation module to check real value of public entities based on technical and fundamental data.
Complementary Tools for Iovance Stock analysis
When running Iovance Biotherapeutics' price analysis, check to measure Iovance Biotherapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Iovance Biotherapeutics is operating at the current time. Most of Iovance Biotherapeutics' value examination focuses on studying past and present price action to predict the probability of Iovance Biotherapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Iovance Biotherapeutics' price. Additionally, you may evaluate how the addition of Iovance Biotherapeutics to your portfolios can decrease your overall portfolio volatility.
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities |
Is Iovance Biotherapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Iovance Biotherapeutics. If investors know Iovance will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Iovance Biotherapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.89) | Revenue Per Share 0.005 | Return On Assets (0.40) | Return On Equity (0.82) |
The market value of Iovance Biotherapeutics is measured differently than its book value, which is the value of Iovance that is recorded on the company's balance sheet. Investors also form their own opinion of Iovance Biotherapeutics' value that differs from its market value or its book value, called intrinsic value, which is Iovance Biotherapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Iovance Biotherapeutics' market value can be influenced by many factors that don't directly affect Iovance Biotherapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Iovance Biotherapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Iovance Biotherapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Iovance Biotherapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.